OXB (LSE: OXB), a leading global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, announced on October 29, 2025, that it has been honored as a Champion in the “Cell & Gene Therapy” category at the 2025 CDMO Leadership Awards Europe, held in Frankfurt.
The esteemed Champion title is awarded to the CDMO that receives the highest score in its category, determined by direct feedback from biopharmaceutical professionals who have recently collaborated with CDMOs. This accolade underscores OXB”s commitment to excellence in quality, innovation, and service throughout its extensive global network.
This recognition arrives during a period of significant commercial growth for OXB, fueled by a rising demand for its comprehensive CDMO services across various key vector types. The organization also boasts an expanding client portfolio that encompasses all development stages.
Dr. Sebastien Ribault, Chief Business Officer of OXB, expressed pride in the recognition, stating, “We are honoured to receive this recognition from the CDMO Leadership Awards Europe. It reflects the trust and satisfaction of our clients and the dedication of our teams across the UK, US, and France. As demand continues to grow, we remain committed to supporting our clients in delivering the next generation of transformative therapies to patients around the world.”
Founded as a pioneer in cell and gene therapy, OXB has accumulated 30 years of expertise in viral vectors, which are crucial to the majority of therapies in this field. The company partners with many of the world”s most innovative pharmaceutical and biotechnology firms, providing specialized viral vector development and manufacturing services for lentivirus, adeno-associated virus (AAV), adenovirus, and other types of viral vectors.
OXB”s capabilities span from early-stage development through to commercialization, supported by robust quality assurance systems and extensive regulatory knowledge. The company offers an array of technologies for viral vector manufacturing, including the advanced 4th generation lentiviral vector system known as the TetraVectaTM system, a dual-plasmid system for AAV production, and various processes using stable producer and packaging cell lines.
Headquartered in Oxford, UK, OXB is a constituent of the FTSE250 and FTSE4Good indices, with development and manufacturing facilities located in Oxfordshire, UK, Lyon and Strasbourg in France, as well as Bedford, MA, and Durham, NC, in the United States.
The CDMO Leadership Awards, organized by Outsourced Pharma and Life Science Connect, recognize contract development and manufacturing organizations that excel in various domains including quality, capabilities, expertise, reliability, and service. Winners are determined based on primary research conducted by Orientation Marketing, reflecting insights from professionals in the biopharmaceutical sector.
For further information, visit www.oxb.com and follow OXB on LinkedIn and YouTube.
